Table 1.
Clinical characteristics of axial spondyloarthritis patients with and without inflammatory bowel disease, and healthy controls
| Assessed parameter | Patients with axSpA and IBD (n = 19) Mean ± SD Median (Q1, Q3) | Patients with axSpA without IBD (n = 142) Mean ± SD Median (Q1, Q3) | Healthy Controls (n = 30) |
|---|---|---|---|
| Age, years | 44.6 ± 10.6 | 46.4 ± 13.3 | 43.5 ± 9.4 |
| axSpA disease duration, years | 10.4 ± 9.5 | 12.1 ± 9,4 | 0 |
| IBD disease duration, years | 8.47 ± 6.9 | 0 | 0 |
| IBD diagnosis preceded axSpA diagnosis, n (%) | 6 (31.6) | 0 | 0 |
| axSpA diagnosis preceded IBD diagnosis, n (%) | 10 (52.6) | 0 | 0 |
| Nonradiographic axSpA, n (%) | 2 (10.5) | 6 (4.2) | 0 |
| Ankylosing spondylitis, n (%) | 17 (89.5) | 136 (95.8) | 0 |
| HLA-B27, n positive/n assessed (%) | 18/19 (94.7) | 109/115 (94.7) | 0 |
| ANCA, n positive/n assessed (%) | 1/5 (20) | 10/62 (16.1) | 0/30 (0) |
| AAU, n (%) | 7 (36.8) | 35 (24.6) | 0 |
| Hypertension, n (%) | 5 (26.3) | 33 (23.2) | 0 |
| Diabetes, n (%) | 0 (0) | 4 (2.8) | 0 |
| IHD, n (%) | 3 (15.7) | 10 (7.0) | 0 |
| Smoking, n (%) | 2 (10.5) | 14 (9.8) | 0 |
| NSAIDs only, n (%) | 0 (0) | 36 (25.3) | 0 |
| Sulfasalazine, n (%) | 12 (63.1) | 76 (53.2) | 0 |
| Adalimumab, n (%) | 6 (31.6) | 6 (4.2) | 0 |
| Golimumab, n (%) | 0 (0) | 1 (0.7) | 0 |
| Infliximab, n (%) | 2 (10.5) | 6 (4.2) | 0 |
| Methotrexate, n (%) | 2 (10.5) | 17 (11.9) | 0 |
| Prednisone, n (%) | 2 (10.5) | 0 (0) | 0 |
AAU acute anterior uveitis, axSpA axial spondyloarthritis, HLA-B27 human leukocyte antigen B27, IBD inflammatory bowel disease, IHD ischemic heart disease, NSAIDs nonsteroidal anti-inflammatory drugs, n number